California Judge Says Biosimilars Law Prohibits Sandoz’s Premature Patent Suit

Drug Industry Daily
A A
A California judge has ruled that Sandoz must file an application with the FDA for approval of a biosimilar referencing Amgen’s biologic arthritis drug Enbrel before it can challenge the brand drug’s patents.

To View This Article:

Login

Subscribe To Drug Industry Daily